ABOUT PALISADE BIO
Advancing Differentiated Oral Therapies for Immune-mediated and Fibrotic diseases
Who We Are and What We’re Building
Palisade Bio is a clinical-stage biopharmaceutical company developing differentiated oral therapeutics for immune-mediated and fibrotic diseases.
Our lead program, PALI-2108, is advancing in inflammatory bowel disease, with a Phase 2 study in ulcerative colitis and a planned Phase 2 study in Crohn’s disease.
Our Mission
Advance differentiated oral therapies that address significant unmet needs in immune-mediated and fibrotic diseases.
Our Vision
Transform validated biology into better tolerated, more convenient medicines for patients living with chronic inflammatory and fibrotic diseases.